Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 4
2010 pubmed 42 citations

Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.

Cerovecki. Tomislav T; Bojanic. Ivan I; Brcic. Luka L; Radic. Bozo B; Vukoja. Ivan I; Seiwerth. Sven S; Sikiric. Predrag P

Key Findings

  • BPC‑157 dramatically improved functional, biomechanical, macroscopic and histological healing of a transected medial collateral ligament in rats.
  • The peptide was effective when delivered intraperitoneally (10 µg daily), orally in drinking water (0.16 µg/ml, ~2 µg/day), or topically as a thin cream layer (1 µg per application).
  • Consistent benefits were observed across all delivery methods over a 90‑day healing period.

Practical Outcomes

  • For biohackers interested in faster ligament repair, BPC‑157 appears promising and can be taken orally or applied topically at microgram‑level doses. While the data are from rats, the study suggests low‑dose, daily administration could be a practical protocol to test, pending human safety and efficacy confirmation.

Summary

In rats with a cut knee ligament, giving the peptide BPC‑157 helped the tissue heal faster and stronger. It worked whether the peptide was injected into the belly, added to drinking water, or applied as a thin cream on the wound, using very small doses.

Abstract

We improved medial collateral ligament (MCL) healing throughout 90 days after surgical transection. We introduced intraperitoneal, per-oral (in drinking water) and topical (thin cream layer) peptide therapy always given alone, without a carrier. Previously, as an effective peptide therapy, stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide effective in inflammatory bowel disease therapy (PL 14736)) particularly improved healing of transected tendon and muscle and wound healing effect including the expression of the early growth response 1 (egr-1) gene. After MCL transection BPC 157 was effective in rats when given once daily intraperitoneally (10 microg or 10 ng/kg) or locally as a thin layer (1.0 microg dissolved in distilled water/g commercial neutral cream) at the site of injury, first application 30 min after surgery and the final application 24 h before sacrifice. Likewise, BPC 157 was effective given per-orally (0.16 microg/ml in the drinking water (12 ml/day/rat)) until sacrifice. Commonly, BPC 157 microg-ng-rats exhibited consistent functional, biomechanical, macroscopic and histological healing improvements. Thus, we suggest BPC 157 improved healing of acute ligament injuries in further ligament therapy.

Study Information

Provider

pubmed

Year

2010

Date

2010-09-01T00:00:00.000Z

DOI

10.1002/jor.21107

Citations

42

References

24